- •Trebananib + PLD did not meet the primary end-point of improving PFS.
- •However, trebananib + PLD improved objective response rate and duration of response.
- •No new safety signals were identified in the ENGOT-ov-6/TRINOVA-2 study.
Trebananib, a peptide-Fc fusion protein, inhibits angiogenesis by inhibiting binding of angiopoietin-1/2 to the receptor tyrosine kinase Tie2. This randomised, double-blind, placebo-controlled phase 3 study evaluated whether trebananib plus pegylated liposomal doxorubicin (PLD) improved progression-free survival (PFS) in patients with recurrent epithelial ovarian cancer.
Women with recurrent ovarian cancer (platinum-free interval ≤12 months) were randomised to intravenous PLD 50 mg/m2 once every 4 weeks plus weekly intravenous trebananib 15 mg/kg or placebo. PFS was the primary end-point; key secondary end-points were objective response rate (ORR) and duration of response (DOR). Owing to PLD shortages, enrolment was paused for 13 months; the study was subsequently truncated.
Two hundred twenty-three patients were enrolled. Median PFS was 7.6 months (95% CI, 7.2–9.0) in the trebananib arm and 7.2 months (95% CI, 4.8–8.2) in the placebo arm, with a hazard ratio of 0.92 (95% CI, 0.68–1.24). However, because the proportional hazards assumption was not fulfilled, the standard Cox model did not provide a reliable estimate of the hazard ratio. ORR in the trebananib arm was 46% versus 21% in the placebo arm (odds ratio, 3.43; 95% CI, 1.78–6.64). Median DOR was improved (trebananib, 7.4 months [95% CI, 5.7–7.6]; placebo, 3.9 months [95% CI, 2.3–6.5]). Adverse events with a greater incidence in the trebananib arm included localised oedema (61% versus 32%), ascites (29% versus 9%) and vomiting (45% versus 33%).
Trebananib demonstrated anticancer activity in this phase 3 study, indicated by improved ORR and DOR. Median PFS was not improved. No new safety signals were identified.
Trial registration: ClinicalTrials.gov, NCT01281254
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- NCCN clinical practice guidelines in oncology: ovarian cancer v.2.2015. National Comprehensive Cancer Network, Fort Washington, PA2015
- Latest research and treatment of advanced-stage epithelial ovarian cancer.Nat Rev Clin Oncol. 2013; 10: 211-224https://doi.org/10.1038/nrclinonc.2013.5
- Challenges for chemotherapy in ovarian cancer.Ann Oncol. 2006; 17: v181-v187https://doi.org/10.1093/annonc/mdj978
- Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.Gynecol Oncol. 2001; 82: 323-328https://doi.org/10.1006/gyno.2001.6272
- The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.Gynecol Oncol. 2001; 81: 206-212https://doi.org/10.1006/gyno.2000.5980
- Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.Gynecol Oncol. 2000; 78: 369-372https://doi.org/10.1006/gyno.2000.5921
- Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.J Clin Oncol. 1997; 15: 987-993
- Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.Gynecol Oncol. 2004; 95: 1-8https://doi.org/10.1016/j.ygyno.2004.07.011
- Role of angiogenesis in tumor growth and metastasis.Semin Oncol. 2002; 29: 15-18https://doi.org/10.1016/S0093-7754(02)70065-1
- Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system.Nat Rev Mol Cell Biol. 2009; 10: 165-177https://doi.org/10.1038/nrm2639
- Angiogenesis-related pathways in the pathogenesis of ovarian cancer.Int J Mol Sci. 2013; 14: 15885-15909https://doi.org/10.3390/ijms140815885
- Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial.J Clin Oncol. 2014; 32: 1302-1308https://doi.org/10.1200/JCO.2013.51.4489
- OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.J Clin Oncol. 2012; 30: 2039-2045https://doi.org/10.1200/JCO.2012.42.0505
- A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213) [abstract].Gynecol Oncol. 2015; 137: 3-4https://doi.org/10.1016/j.ygyno.2015.01.005
- Incorporation of bevacizumab in the primary treatment of ovarian cancer.N Engl J Med. 2011; 365: 2473-2483https://doi.org/10.1056/NEJMoa1104390
- A phase 3 trial of bevacizumab in ovarian cancer.N Engl J Med. 2011; 365: 2484-2496https://doi.org/10.1056/NEJMoa1103799
- AGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy ± nintedanib for advanced ovarian cancer [abstract].Int J Gyn Cancer. 2013; 23: PL01
- Incorporation of pazopanib in maintenance therapy of ovarian cancer.J Clin Oncol. 2014; 32: 3374-3382https://doi.org/10.1200/JCO.2014.55.7348
- Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet. 2016; 387: 1066-1074https://doi.org/10.1016/S0140-6736(15)01167-8
- Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.Gynecol Oncol. 2015; 139: 10-16https://doi.org/10.1016/j.ygyno.2015.08.004
- Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.Cancer Cell. 2004; 6: 507-516https://doi.org/10.1016/j.ccr.2004.09.030
- Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.Mol Cancer Ther. 2010; 9: 2641-2651https://doi.org/10.1158/1535-7163.MCT-10-0213
- A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.Gynecol Oncol. 2014; 135: 25-33https://doi.org/10.1016/j.ygyno.2014.07.003
- Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.J Clin Oncol. 2012; 30: 362-371https://doi.org/10.1200/JCO.2010.34.3178
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.Lancet Oncol. 2014; 15: 799-808https://doi.org/10.1016/S1470-2045(14)70244-X
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer. 2009; 45: 228-247https://doi.org/10.1016/j.ejca.2008.10.026
- European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies.Int J Gynecol Cancer. 2010; 20: 476-478https://doi.org/10.1111/IGC.0b013e3181d3caa8
Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v3.0 (CTCAE). Available at: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf. [Accessed 2 December 2015].
- The functional assessment of cancer therapy scale: development and validation of the general measure.J Clin Oncol. 1993; 11: 570-579
- EuroQol: the current state of play.Health Policy. 1996; 37: 53-72
- Checking the Cox model with cumulative sums of martingale-based residuals.Biometrika. 1993; 80: 557-572https://doi.org/10.1093/biomet/80.3.557
- The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.Eur J Cancer. 2006; 42: 3127-3139
- MITO-11: a randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC).J Clin Oncol. 2014; 32: 5503
- Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial.J Clin Oncol. 2015; 33: 3836-3838https://doi.org/10.1200/JCO.2015.63.1408
- Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free survival-2.Gynecol Oncol. 2016; 143: 27-34
- Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.Gynecol Oncol. 2015; 139: 17-22https://doi.org/10.1016/j.ygyno.2015.07.103
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.Lancet Oncol. 2015; 16: 928-936https://doi.org/10.1016/s1470-2045(15)00086-8
- Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures.World J Gastrointest Surg. 2012; 4: 87-95
- Malignant ascites in ovarian cancer and the role of targeted therapeutics.Anticancer Res. 2014; 34: 1553-1561
Published online: December 02, 2016
Accepted: September 1, 2016
Received in revised form: August 26, 2016
Received: June 24, 2016
Research support: This work was funded by Amgen Inc.
© 2016 Published by Elsevier Ltd.